Portage Biotech Inc Ord (PRTG)

$7.84 +1.09 (16.15%)
Market Cap 8.22M
Revenue (ttm) 0.00
Net Income (ttm) -75.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 861,600
Avg Vol 1,356,148
Day's Range N/A - N/A
Shares Out 1.05M
Stochastic %K 38%
Beta 0.54
Analysts Strong Buy
Price Target $140.00

Latest News on PRTG

Why Is Portage Biotech Stock Skyrocketing Friday?

Mar 28, 2025, 1:13 PM EDT - 23 days ago

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Mar 27, 2025, 6:02 PM EDT - 24 days ago

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Mar 12, 2025, 8:00 AM EDT - 5 weeks ago

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Feb 12, 2025, 4:15 PM EST - 2 months ago

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Announces Completion of $2.15 Million Private Financing

Jan 30, 2025, 4:30 PM EST - 2 months ago

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Jan 6, 2025, 5:00 AM EST - 3 months ago

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Dec 12, 2024, 4:15 PM EST - 4 months ago

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Nov 26, 2024, 4:05 PM EST - 5 months ago

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Apr 12, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Mar 26, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Feb 28, 2024, 5:10 PM EST - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Portage Biotech Reports Business and Strategic Update

Jan 4, 2024, 8:00 AM EST - 1 year ago

Portage Biotech Reports Business and Strategic Update

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Nov 28, 2023, 4:01 PM EST - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Nov 6, 2023, 8:01 AM EST - 1 year ago

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Portage Biotech Announces $6.0 Million Registered Direct Offering

Sep 29, 2023, 8:00 AM EDT - 1 year ago

Portage Biotech Announces $6.0 Million Registered Direct Offering

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Sep 20, 2023, 8:00 AM EDT - 1 year ago

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Jul 31, 2023, 4:05 PM EDT - 1 year ago

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Mar 1, 2023, 8:00 AM EST - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Feb 27, 2023, 4:05 PM EST - 2 years ago

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Feb 15, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Nov 29, 2022, 4:43 PM EST - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 9:00 AM EST - 2 years ago

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Nov 8, 2022, 8:00 AM EST - 2 years ago

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Portage Biotech Provides Research and Development Update

Sep 14, 2022, 8:39 AM EDT - 2 years ago

Portage Biotech Provides Research and Development Update

Portage Biotech to Present at Upcoming Investor Conferences

Sep 8, 2022, 8:00 AM EDT - 2 years ago

Portage Biotech to Present at Upcoming Investor Conferences

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Aug 29, 2022, 8:00 AM EDT - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Portage Biotech Announces Leadership Updates

Aug 18, 2022, 8:00 AM EDT - 2 years ago

Portage Biotech Announces Leadership Updates

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 9:10 AM EDT - 2 years ago

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 8:00 AM EDT - 2 years ago

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Jul 20, 2022, 4:07 PM EDT - 2 years ago

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Jul 20, 2022, 9:00 AM EDT - 2 years ago

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Jul 6, 2022, 4:05 PM EDT - 3 years ago

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Apr 13, 2022, 10:00 AM EDT - 3 years ago

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Mar 31, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Mar 9, 2022, 9:00 AM EST - 3 years ago

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Feb 24, 2022, 5:43 PM EST - 3 years ago

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Portage Biotech Announces New Appointments to its Management Team and Board of Directors

Feb 15, 2022, 8:00 AM EST - 3 years ago

Portage Biotech Announces New Appointments to its Management Team and Board of Directors

Portage Biotech Announces Participation in January 2022 Investor Conferences

Jan 5, 2022, 8:00 AM EST - 3 years ago

Portage Biotech Announces Participation in January 2022 Investor Conferences

Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

Nov 23, 2021, 8:00 AM EST - 3 years ago

Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

Nov 22, 2021, 4:53 PM EST - 3 years ago

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics' INT230-6 (PORT-1) at November Scientific Conferences

Nov 15, 2021, 8:00 AM EST - 3 years ago

Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics' INT230-6 (PORT-1) at November Scientific Conferences